This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Diabetes Animal Model Development
BioVenic offers end-to-end Diabetes Animal Model Development Services tailored for biopharmaceutical companies and academic researchers evaluating novel anti-diabetic therapeutics, insulin sensitizers, and metabolic disease mechanisms. We provide customized model generation, disease validation, and preclinical efficacy screening across rodents (mice, rats) and non-rodent species (rabbits, swine, canines). BioVenic’s full-service platform supports Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), gestational diabetes, and diabetic complication models (nephropathy, neuropathy, retinopathy), complete with blood glucose monitoring, HbA1c profiling, glucose/insulin tolerance tests (GTT/ITT), and histopathological validation.
Background
The majority of diabetics fall into two main categories: T1DM and T2DM, each with its own unique pathophysiological characteristics. Diabetes can cause a variety of complications that affect the performance and health of the animal. Therefore, it is necessary to develop animal models to study the mechanism of diabetes and to develop therapies for animal diabetes.
T1DM
- Cause: The body's immune system attacks and destroys beta cells in the pancreas responsible for producing insulin. This results in a lack of insulin, a crucial hormone for regulating blood sugar levels and facilitating glucose uptake by cells.
- Influencing Factors: Family history may influence the risk
- Management: Individuals with T1DM rely on lifelong insulin therapy to control their blood glucose levels.
T2DM
- Cause: insulin resistance, wherein the body's cells do not respond effectively to insulin, accompanied by a relative insulin deficiency.
- Influencing Factors: This form of diabetes is often associated with factors like obesity, sedentary lifestyle, and/or genetic predisposition.
- Management: T2DM is typically managed through lifestyle modifications and oral medications.
Diabetes Animal Model Development
Animal models have been indispensable in testing innovative medicinal approaches since the early testing of insulin in dogs almost a century ago. Based on the methodologies used for their development, diabetes animal models can be categorized into chemically induced, genetically/spontaneously induced, virus-induced, surgically constructed, and diet/nutrition-induced animal models.
- Chemically Induced Diabetes Animal Model Development
Chemicals such as alloxan and streptozotocin (STZ) have been commonly used to produce animals with T1DM, although other agents such as cyclophosphamide and multiple low-dose streptozotocin (MLD-STZ) have also been used. Administration of sub diabetogenic doses of STZ or alloxan can lead to impaired glucose tolerance, which closely resembles the early stages of T2DM. BioVenic can assist in selecting the appropriate dose of these drugs to induce diabetes depending on factors such as species, route of administration and nutritional status.
- Genetically/Spontaneously Induced Diabetes Animal Model Development
Diabetes animal models for both T1DM and T2DM have been developed through spontaneous induction and genetic engineering. Numerous rat and mouse models, induced either genetically or spontaneously, have been extensively utilized in diabetes research. We have established cutting-edge Animal Breeding and Genetics technology platforms that cater to multiple species. By leveraging our expertise, we can provide assistance in your genetically/spontaneously induced diabetes animal model development project.
- Virus-Induced Diabetes Animal Model Development
In order to create animal models for T1DM, viruses have been utilized to target and eliminate insulin-producing β cells in the pancreas. Prominent viruses employed in these models include Coxsackie B virus (CBV), Encephalomyocarditis virus (EMCV), Lymphocytic choriomeningitis virus (LCMV), Cytomegalovirus (RCMV), and the Kilham virus. By tailoring our approach to your project and research goals, we can offer specific solutions for inducing diabetes using viruses.
- Surgically Constructed Diabetes Animal Model Development
For the study of T1DM, essential surgical techniques involve complete removal of the pancreas (pancreatectomy), transplantation of insulin-producing islets, and surgical removal of the thymus gland (thymectomy). Surgical methods to induce T2DM primarily focus on reducing the mass of pancreatic β cells. At BioVenic, we offer a range of products and services to assist you in building your own diabetes animal models through surgical procedures.
- Diet/Nutrition-Induced Diabetes Animal Model Development
Selective breeding is an effective approach to produce animals with impaired glucose tolerance. BioVenic offers clients various dietary and nutritional strategies to generate animal models for studying the progression of T2DM and testing potential treatments. Our common methods include the use of high fat diets (HFD) to induce obesity and insulin resistance, as well as energy dense diets (ED). In addition, we can provide solutions for combining diet with low-dose STZ to create HFD/ STZ animal models of T2DM.
- Combinations-Induced Diabetes Animal Model Development
By combining chemical agents with HFD, nicotinamide, or genetically susceptible animals, conditions can be induced that closely resemble T2DM, marked by insulin resistance and progressive β cell dysfunction. These combinations enable researchers to generate a more controlled and reproducible T2DM phenotype in animals. With our integrated solutions, BioVenic offers researchers a tailored approach for developing diabetes animal models.
- Diabetes Animal Model Validation
In order to establish reliable and successful animal models for understanding disease susceptibility and pathogenesis in diabetes, validation is crucial. We offer a range of assays for diabetes biomarkers (such as insulin, serum glucose, and C-peptide) in different animal species. These assays not only help confirm the induction of diabetes in animal models but also allow for the measurement of important biomarkers in your diabetes research through our Animal Nutrition and Metabolism Analysis services.
Related Research: Validation and Application of STZ-Induced Diabetic Animal Models
In recent metabolic research, adult male Wistar albino rats were utilized to establish a robust type 2 diabetes mellitus (T2DM) model via streptozotocin (STZ) induction. This experimental model was effectively applied to evaluate the therapeutic potential and underlying mechanisms of tauroursodeoxycholic acid (TUDCA) in mitigating diabetic complications. The study demonstrated that STZ-induced diabetic rat models provide a highly reliable in vivo platform for evaluating candidate compounds aimed at restoring glycemic control, improving insulin sensitivity, and regulating lipid homeostasis. Furthermore, this model allows for detailed molecular investigation into how therapeutic interventions can alleviate systemic lipotoxicity, attenuate oxidative and nitrosative stress, suppress pro-inflammatory cytokine expression, and reduce pancreatic beta-cell apoptosis. Overall, STZ-induced rodent models serve as an essential preclinical tool for dissecting complex metabolic pathways and accelerating drug discovery for diabetes management.
Fig. 1 TUDCA decreased the levels of serum glucose, HbA1c% , and HOMA-IR and increased insulin in STZ-induced diabetic rats1
Diabetes Animal Model Development Workflow
Why Choose Us?
To meet your specific research requirements, our solutions offer effective methods to induce both T1DM and T2DM in various animal species.
Recognizing the significance of diabetes research using animal models, we are dedicated to providing you with the necessary support.
Our commitment to staying updated on the latest developments in diabetes research in animals ensures that we remain a valuable research partner.
Our comprehensive services encompass the development, evaluation, and facilitation of drug or therapy research using diabetes animal models.
Case Study: High-Fat Diet + STZ-Induced Type 2 Diabetes Rodent Model for Efficacy Evaluation
Study Goal: Establish a robust, stable Type 2 Diabetes rodent model to evaluate the therapeutic efficacy of a client's investigational small-molecule compound (Target X).
Model Design:
Animals: Male C57BL/6J mice (6 weeks old).
Induction: 4 weeks of 60% High-Fat Diet (HFD) followed by a low-dose Streptozotocin injection (STZ, 35 mg/kg, i.p. for 2 consecutive days).
Validation & Readouts: Fasting blood glucose (FBG) > 16.7 mmol/L verified hyperglycemia. IPGTT (2 g/kg glucose) performed at Week 6 demonstrated pronounced glucose intolerance compared to normal chow controls.
Results & Key Findings: Treatment with Compound X significantly decreased fasting blood glucose levels by 38% and restored glucose tolerance AUC (Area Under the Curve) in a dose-dependent manner over a 4-week treatment period without acute toxicity.
Fig. 2 Key Outcomes of a Case Study
Frequently Asked Questions
Q1: What species and induction methods does BioVenic offer for T1D and T2D animal models?
A: BioVenic provides T1D models primarily induced by high-dose Streptozotocin (STZ) or autoimmune spontaneous strains (NOD mice). For T2D, we utilize low-dose STZ combined with High-Fat Diet (HFD), genetically modified models (db/db, ob/ob, KK-Ay), and surgical models across mice, rats, and non-human primates.
Q2: What phenotype validation metrics are included in BioVenic's diabetes model development?
A: Standard validation includes continuous blood glucose monitoring, intraperitoneal/oral glucose tolerance tests (IPGTT/OGTT), insulin tolerance tests (ITT), serum insulin and HbA1c measurement (ELISA), body weight tracking, and pancreatic islet histopathology (H&E and Insulin/Glucagon IHC staining).
Q3: What is the typical timeline for custom diabetes model establishment?
A: Timelines depend on the model type and animal species: chemically induced rodent models take approximately 4-8 weeks including stabilization and readout, whereas genetic or surgical models may require 10-16 weeks.
We deeply comprehend the significance of diabetes research on animal models and are enthusiastic about offering our services. Whether you need help developing diabetes animal models for preclinical studies or developing protocols to study nutritional and metabolic diseases in animals, BioVenic is ready to help. If you have any requirements or inquiries regarding diabetes animal model development, please do not hesitate to contact us.
Reference
- Mohamed, Nema A., et al. "Tauroursodeoxycholic acid (TUDCA) relieves streptozotocin (STZ)-induced diabetic rat model via modulation of lipotoxicity, oxidative stress, inflammation, and apoptosis." International Journal of Molecular Sciences 25.13 (2024): 6922. https://doi.org/10.3390/ijms25136922. Distributed under Open Access license CC BY 4.0. The original title was changed to "TUDCA decreased the levels of serum glucose, HbA1c% , and HOMA-IR and increased insulin in STZ-induced diabetic rats".